Compare Inovio Pharmaceuticals Inc (INO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Warner Music Group Corp trades at $25.06 (market cap $13.12B). The key difference: Warner Music Group Corp is far larger — about 167× Inovio Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 3.19% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WMG | |
|---|---|---|
Market Cap | $78.55M | $13.12B |
Sector | Health | Media |
52-Week High | $2.87 | $34.72 |
52-Week Low | $0.66 | $23.65 |
Enterprise Value | $49.56M | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Warner Music Group (WMG) trades at $24.78, down 6.17% in the past 24 hours, with a bearish technical signal and support near $23. Recent earnings show mixed results, with Q1 and Q2 2026 beats but Q3 and Q4 2025 misses. Revenue grew to $6.71B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, citing streaming growth and strategic renewals like the NetEase Cloud Music partnership announced July 16, 2026.
The outlook is cautiously optimistic, with strong analyst support and projected revenue growth to $7.3B in 2026. Risks include execution challenges amid leadership changes, competitive pressures, and market volatility. The current valuation at a P/E of 20.06 may appeal to growth-oriented investors, but near-term price weakness reflects earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
